Mark King, RPH in Abernathy, TX - Pharmacist

Mark King, RPH is a Pharmacist based in Abernathy, Texas. Mark King is licensed to practice in Texas (license number 31332) and his current practice location is 920 Avenue D, Abernathy, Texas. He can be reached at his office (for appointments etc.) via phone at (806) 298-2222.

NPI number for Mark King is 1275668402 and his current mailing address is 920 Avenue D, Abernathy, Texas. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1275668402.

Contact Information

	Mark King, RPH
	920 Avenue D, Abernathy, TX 79311-3437
	(806) 298-2222
	Not Available

Healthcare Provider's Profile

Full Name	Mark King
Gender	Male
Speciality	Pharmacist
Location	920 Avenue D, Abernathy, Texas
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1275668402
Provider Enumeration Date: 02/21/2007
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Mark King such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1275668402	NPI	-	NPPES
144622	Medicaid	TX

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
183500000X	Pharmacist	31332 (Texas)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mark King is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mark King, RPH 920 Avenue D, Abernathy, TX 79311-3437 Ph: () -	Mark King, RPH 920 Avenue D, Abernathy, TX 79311-3437 Ph: (806) 298-2222

News Archive

DEKRA, Health Canada clear ORTHOCON's new Absorbable Bone Hemostat Matrix

ORTHOCON, Inc., a privately-held therapeutic device company, today announced that DEKRA and Health Canada have cleared its HEMASORB Absorbable Bone Hemostat Matrix for clinical use and sale in Europe and Canada.

Co-existing non-communicable diseases linked to higher risk of illness and death from COVID-19

The interaction of COVID-19 with co-existing non-communicable diseases (NCDs) is a perfect storm, particularly for communities of poverty, according to a new opinion piece published by Columbia Mailman School of Public Health researchers in the journal British Medical Journal.

Generics as good as brand-name drugs when treating heart diseases

Contrary to the perception of some patients and physicians, there is no evidence that brand-name drugs are clinically superior to their generic counterparts, according to an article in the December 3 issue of JAMA, which examined studies comparing the effectiveness of generic vs. brand-name drugs for treating cardiovascular diseases.

Type of alleged crime can increase jurors' confidence in guilt, finds new study

The more severe a crime, the more evidence you should have to prove someone did it. But a new Duke study, appearing Oct. 29 in Nature Human Behavior, has shown that the type of alleged crime can increase jurors' confidence in guilt.

Mark King, RPH - Pharmacist in Abernathy, TX